Depressive Disorder News and Research RSS Feed - Depressive Disorder News and Research

Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Obesity, smoking, alcohol abuse, depressive disorders are risk factors for low back pain

Obesity, smoking, alcohol abuse, depressive disorders are risk factors for low back pain

New research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) identifies nicotine dependence, obesity, alcohol abuse and depressive disorders as risk factors for low back pain, a common condition causing disability, missed work, high medical costs and diminished life quality. [More]
Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI). [More]
Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. [More]
Study finding suggests importance of individually-tailored treatment for depression

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression. [More]
Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

A recent study published in the March 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry finds that Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT). [More]
Pain from social rejection lasts longer for people with untreated depression

Pain from social rejection lasts longer for people with untreated depression

Rejected by a person you like? Just "shake it off" and move on, as music star Taylor Swift says. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Brain scans can predict therapeutic responses to talk therapy

Brain scans can predict therapeutic responses to talk therapy

UNC School of Medicine researchers have shown that brain scans can predict which patients with clinical depression are most likely to benefit from a specific kind of talk therapy. [More]
Chronic pain common in affective disorders

Chronic pain common in affective disorders

Patients with major depressive disorder or bipolar disorder frequently report chronic pain at multiple sites, research shows. [More]
Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Nearly three-quarters of homeless adults with mental illness in Canada show evidence of cognitive deficits, such as difficulties with problem solving, learning and memory, new research has found. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
Study highlights public health significance of depression among U.S. adolescents

Study highlights public health significance of depression among U.S. adolescents

A recent study published in the January 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry underscores the important public health significance of depression among U.S. adolescents. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." [More]
Health promotion program reduces cardiovascular risk in obese people with serious mental illness

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

A health promotion program, called In SHAPE, specifically designed for people with serious mental illness, produced more fit participants and significant weight loss than a control group where participants only received a gym membership. [More]
People need to watch distinct warning signs of holiday depression

People need to watch distinct warning signs of holiday depression

While the holidays are a time of merriment and festivities for many, some people struggle with depression during this time of year. [More]
Going to bed late evenings linked to repetitive negative thoughts

Going to bed late evenings linked to repetitive negative thoughts

When you go to bed, and how long you sleep at a time, might actually make it difficult for you to stop worrying. So say Jacob Nota and Meredith Coles of Binghamton University in the US, who found that people who sleep for shorter periods of time and go to bed very late at night are often overwhelmed with more negative thoughts than those who keep more regular sleeping hours. [More]
UT Arlington researcher receives grant to educate Hispanic patients about depression, treatment options

UT Arlington researcher receives grant to educate Hispanic patients about depression, treatment options

A University of Texas at Arlington researcher hopes to dispel myths about depression and its treatment, as well as reduce the stigma associated with receiving mental health care among Hispanics. [More]
Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million. [More]
Advertisement
Advertisement